VISEN Pharmaceuticals (FRA:T06) Intangible Assets: €0.15 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T06 VISEN Pharmaceuticals FRA:T06
7 GF Score
Price €2.06
! 5 Warning Signs
View Full Analysis

What is VISEN Pharmaceuticals Intangible Assets?

VISEN Pharmaceuticals FRA:T06 7 Intangible Assets is €0.15 Mil as of Jun. 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. VISEN Pharmaceuticals's intangible assets for the quarter that ended in Jun. 2026 was €0.15 Mil.

VISEN Pharmaceuticals  (FRA:T06) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.

Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.

VISEN Pharmaceuticals Intangible Assets Related Terms

VISEN Pharmaceuticals Intangible Assets Historical Data

* Premium members only.

The historical data trend for VISEN Pharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VISEN Pharmaceuticals Intangible Assets Chart

VISEN Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Intangible Assets
1.44 1.21 1.13 0.13

VISEN Pharmaceuticals Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Intangible Assets Get a 7-Day Free Trial 0.00 1.13 0.00 0.13 0.15
FRA:T06
7GF Score
VISEN Pharmaceuticals FRA:T06
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VISEN Pharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of €0.15 Mil mean?
VISEN Pharmaceuticals (FRA:T06) has a Intangible Assets of €0.15 Mil as of Jun. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' Intangible Assets too high?
VISEN Pharmaceuticals' current Intangible Assets is €0.15 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Intangible Assets compare to ZTS?
VISEN Pharmaceuticals' Intangible Assets of €0.15 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Drug Manufacturers company?
A good Intangible Assets depends on the Drug Manufacturers industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current Intangible Assets is €0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Intangible Assets of €0.15 Mil. The current Intangible Assets is €0.15 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Intangible Assets is €0.15 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VISEN Pharmaceuticals Business Description

Other Exchanges 02561:Hong Kong
Address 69 Jiuzhang Road, Suite 3-108, Floor 3, Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, CHN
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score

Get the complete analysis for FRA:T06

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price